Circle Pharma, Inc. was founded in 2012 by Matt Jacobson and Scott Lokey and initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP. The company is headquartered in South San Francisco, California, and is a clinical-stage biotechnology company developing bioavailable macrocyclic peptide therapeutics against challenging intracellular protein-protein interactions. Circle Pharma’s proprietary MXMO™ platform combines computational structure-based design with innovative chemistry to create macrocycles that can reach targets that conventional medications cannot. The company has raised over $212 million in funding, including Series B and C financing from The Column Group and NextTech Invest, and focuses its internal pipeline development on intracellular protein-protein interactions that play key roles in cancer. Circle Pharma’s lead candidate, CID-078, is a first-in-class oral macrocycle cyclin A/B RxL inhibitor currently in clinical development, and the company recently announced a research collaboration with Boehringer Ingelheim to develop novel precision cancer treatments.